BioWorld | The Daily Biopharmaceutical News Source

AAN 2018

Better pain drugs necessary part of opioid epidemic fight

LOS ANGELES – At the American Academy of Neurology (AAN) annual meeting this week, Walter Koroshetz pointed out two causes of the opioid epidemic that are obvious in one sense. But ending the opioid epidemic will require figuring out a way to address the relationship between them.

Opioids

Better pain drugs necessary part of opioid epidemic fight

CKD

Corvidia's $60M series B fuels CKD, heart research; phase II trial reports soon

IPR

IPR proceedings survive constitutional challenge in 7-2 Supreme Court ruling

Adcom

Like the FDA, adcom struggles with baricitinib safety data

Top Headlines

Current BioWorld Today Issue »

Latest News

U.S.Yale prof: Drug-coupon 'kickbacks' lead to hamstrung PBMs and raise drug costs

EUROPESosei lands $200M to fund six Heptares’ programs, including dementia

In The ClinicApricus shares tank on yet-another FDA CRL on ED candidate

Deals And M&AU.S./China cross-border deals off to good start, but will 2018 be 'Legend'ary?

FinancingsEvolus seeks $75M to bring back aesthetic market entry

Newco NewsSecarna puts a new twist into an old antisense story

RegulatoryHouse passes spending bill, giving a boost to the NIH and opioid fight, with a bit extra for FDA

Analysis

As HCV cedes to NASH, iterative improvement will be hard to find

The outlook for the future of hepatitis C virus (HCV) treatment seemed to split into two distinct camps at the 2018 International Liver Congress (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), held this month in Paris.

Data

BioWorld Snapshots »

Money raised by biotech in 2018 vs. 2017 »

Socially conscious investing benefits AACR, UBS’ Optimus »

Week in review »

Week in Washington »

Regulatory submissions, approvals and other actions: March 2018 »

The BioWorld Biome

Our Habitat for All Things Science

GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.